Date: June 10th, 2020
Source: Office of Scientific R&D, JNU 
Author: Yanfang

JNU and Guangzhou LiXin Pharmaceuticals held the signing ceremony for their industry-academy cooperation and the transfer of a new drug project of category 1 of chemical drugs on June 8. JNU established the Joint Laboratory of Innovative Drug Development with LiXin and transferred the exclusive global market development rights to JND32066, an innovative anti-tumor drug project in category 1 of chemical drugs, to LiXin with RMB 100 million. JNU President Song Xianzhong and LiXin Chairman Gao Yueyi spoke at the signing ceremony.
During the ceremony, Song and Gao signed the Co-development Contract of JND32066y. JNU Vice President Hong An and Shao Liming, a director of LiXin, signed the Cooperation Agreement of Industry-Academy Cooperation Between Guangzhou LiXin Pharmaceuticals and JNU.
 

(The signing ceremony)
Under the agreement, LiXin paid RMB 100 million for the exclusive global market development rights to JND32066, investing and cooperating to further promote commercialization of the innovative drug.
Early research shows that JND32066, an innovative anti-tumor drug project, has stable medicinal properties and huge market prospects.
Meanwhile, LiXin Pharmaceuticals invested 10 million RMB to build the Joint Laboratory of Innovative Drug Development, a research and development platform for new anti-tumor drugs, with the team of Prof. Ding Ke, dean of JNU's College of Pharmacy and director of the Institute of Pharmacochemical Biology. Through the deep cooperation with JNU, LiXin Pharmaceuticals plans to develop five or six global initiative projects of category 1 of chemical drugs in the next three years.
Before the signing ceremony, Ding gave an introduction to JNU's first-class disciplines of JNU and main cooperative programs. He said the team had built a well-equipped, multidisciplinary research platform for pharmacy and chemical biology, integrating drug chemistry, chemical biology, structural biology, and pharmacodynamic evaluation and mechanism of action. In recent years, this team has made a series of achievements on innovative drugs. Ding emphasized the drug's significant anti-tumor activity in vitro and in vivo, demonstrated by the early data. According to the activity of Fibroblast Growth Factor Receptor and Tyrosine Kinase and other frontier target points, he also revealed the broad application of the tumor spectrum.